The correlation between epithelial-to-mesenchymal transition and resistance to erlotinib (an EGFR tyrosine kinase inhibitor effective in the presence of EGFR activating mutations) has been demonstrated in non-small cell lung cancer. This evidence concerns the gene EGFR and non-small cell lung carcinoma.